Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM53JW0)

Drug Name
CB1 antagonist, Bayer Drug Info
Synonyms
2-[(2,6-dichloro-3-methylphenyl)amino]benzoate; CHEMBL876; CL-583.NA SALT; meclofenamic acid(1-); UPCMLD-DP012; AC1L1H9Q; UPCMLD-DP012:001; CTK5I4915; CHEBI:76230; BDBM50012896; MCULE-3600081195; CCG-204812; NCGC00023217-05; NCGC00023217-04; NCGC00023217-03; NCGC00023217-06; ZB000384; 2-(2,6-dichloro-3-methylanilino)benzoate; AB00053494; AB00053494_19; 2-(2,6-dichloro-3-methyl-phenylamino)-benzoate; 2-(2,6-dichloro-3-methyl-phenylamino)-benzoate(Fenamate series)
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Preclinical [1]
Cross-matching ID
PubChem CID
4036
ChEBI ID
CHEBI:76230
TTD Drug ID
DM53JW0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Cannabinoid receptor 1 (CB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [2]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [3]
Orlistat DMRJSP8 Obesity 5B81 Approved [4]
SR141716A DMCO5JZ Obesity 5B81 Approved [5]
Tebipenem DMVSX6O Urinary tract infection GC08 Phase 3 [1]
Conatumumab DM2UOSN Colorectal cancer 2B91.Z Phase 2 [6]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [7]
SR-147778 DMNAECP Obesity 5B81 Phase 2 [8]
Nimacimab DM21Z68 Diabetic nephropathy GB61.Z Phase 2 [9]
AEF0117 DMQ1GH4 Marijuana use disorder 6C41 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Antagonist [1]

References

1 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
2 Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
3 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
4 Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
5 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
6 Clinical pipeline report, company report or official report of AstraZeneca (2009).
7 Company report (Gwpharm)
8 Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
9 Clinical pipeline report, company report or official report of Bird Rock Bio.
10 Clinical pipeline report, company report or official report of Affimed Therapeutics.